Compare TRDA & GRVY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRDA | GRVY |
|---|---|---|
| Founded | 2016 | 2000 |
| Country | United States | South Korea |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.6M | 431.2M |
| IPO Year | 2021 | 2005 |
| Metric | TRDA | GRVY |
|---|---|---|
| Price | $14.19 | $61.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $21.00 | N/A |
| AVG Volume (30 Days) | ★ 162.5K | 17.2K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,421,000.00 | N/A |
| Revenue This Year | $39.97 | N/A |
| Revenue Next Year | $50.80 | N/A |
| P/E Ratio | ★ N/A | $8.05 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.93 | $54.54 |
| 52 Week High | $14.36 | $74.75 |
| Indicator | TRDA | GRVY |
|---|---|---|
| Relative Strength Index (RSI) | 61.47 | 44.29 |
| Support Level | $10.84 | $60.05 |
| Resistance Level | N/A | $64.83 |
| Average True Range (ATR) | 0.75 | 1.54 |
| MACD | 0.12 | 0.02 |
| Stochastic Oscillator | 87.79 | 24.95 |
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
GRAVITY Co Ltd is an online and mobile games developer and publisher based in Korea. Its principal product, Ragnarok Online, is an online game which is available in more than 91 markets. Its games include Ragnarok Online, Requiem, Dragonica (Dragon Saga), Ragnarok Online II, Requiem Online, and R.O.S.E. Online. The company generates revenue from online games, mobile games and other sources including character based merchandise and animation.